FDA: Samsca may cause irreversible liver damage

FDA: samsca may cause irreversible liver damage
Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.

(HealthDay)—Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.

The FDA and Otsuka notified health care providers of this potential risk after three patients with Autosomal Dominant (ADPKD) participating in a drug trial developed significant increases in serum alanine aminotransferase, along with significant increases in serum total bilirubin. The patients were taking a higher dose (90 mg in the morning and 30 mg in the afternoon) than the 60-mg dose approved for hyponatremia. Samsca is not approved for treating of ADPKD.

An external panel of liver experts determined that tolvaptan was most likely the culprit in these three cases; all of the patients improved once they stopped taking the drug.

" should perform liver tests promptly in patients who report symptoms that may indicate liver injury," the authors write. "If hepatic injury is suspected, Samsca should be promptly discontinued, appropriate treatment should be instituted, and investigations should be performed to determine probable cause. Samsca should not be re-initiated in patients unless the cause for the observed is definitively established to be unrelated to treatment with Samsca."


Explore further

Mayo Clinic identifies promising treatment for inherited form of kidney disease

More information: More Information

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: FDA: Samsca may cause irreversible liver damage (2013, January 26) retrieved 20 August 2019 from https://medicalxpress.com/news/2013-01-fda-samsca-irreversible-liver.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more